Berkeley, CA, February 18, 2021 – GeneTether Inc., a Bay Area biotech company focused on developing technologies to increase the correction efficiency of targeted genome editing technologies, today announced that the Australian Patent Office has granted Australian Patent No. AU 2019244594 for its DNA Template-Nuclease-Tethering, or TNT™, platform with a priority date of March 25, 2018.
GeneTether’s Co-Founder and Chief Scientific Officer, Dr. Geoffrey Sargent, said: “We believe our TNT™ platform will be a critical component in achieving the efficiency levels required to make CRISPR-mediated gene replacement possible on a commercially-viable scale. The allowance of GeneTether’s patent by the Australian Patent Office provides a fundamental piece of intellectual property protection for our platform and validates the significant research and development we have conducted to date. We look forward to additional patent grants from our eight pending applications around the world.”
About GeneTether
GeneTether has developed a proprietary method to conjugate, or “tether,” donor DNA templates to targeted genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs. We refer to this as our DNA Template-Nuclease Tethering, or TNT™, Platform. In ex vivo experimentation combining our TNT™ Platform technology with CRISPR-Cas9, the TNT™ Platform has been shown to increase editing efficiency to >50%.
For more information, visit www.genetether.com.
For inquiries, please contact us at:
Har Grover, CEO
[email protected]
Comments are closed